NCT01458288View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Multiple MyelomaNon-hodgkin's LymphomaHodgkin's Disease
Interventions
DRUG

TG-0054

3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)

Trial Locations (1)

11794

Stony Brook University Hospital, Stony Brook

Sponsors
All Listed Sponsors
lead

GPCR Therapeutics, Inc.

INDUSTRY